Metraipolis › archive › dc_cf972de85d57
ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases — Europe PMC PMID:41050403
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41050403
- DOI
- 10.3389/fphar.2025.1640090
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T21:02:58.953Z
- SHA-256 of the archived text
59238ac92f0ae8455e0ef9715902b0f9eef594475c56d7de5ad7cf9a65080eb4- Stable URL of this page
https://metraipolis.com/documento/dc_cf972de85d57
How to cite
ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases — Europe PMC PMID:41050403 — Europe PMC (en), https://europepmc.org/article/MED/41050403 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf972de85d57 (Metraipolis archive dc_cf972de85d57, sha256 59238ac92f0ae8455e0ef9715902b0f9eef594475c56d7de5ad7cf9a65080eb4)
BibTeX
@misc{dccf972de85d57,
title = {ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases — Europe PMC PMID:41050403},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41050403},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf972de85d57; sha256 59238ac92f0ae8455e0ef9715902b0f9eef594475c56d7de5ad7cf9a65080eb4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41050403. Agents can read the archived copy with the MCP tool read_document.